These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35583694)

  • 1. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
    Merola E; Pascher A; Rinke A; Bartsch DK; Zerbi A; Nappo G; Carnaghi C; Ciola M; McNamara MG; Zandee W; Bertani E; Marcucci S; Modica R; Grützmann R; Fazio N; de Herder W; Valle JW; Gress TM; Fave GD; de Pretis G; Perren A; Wiedenmann B; Pavel ME
    Ann Surg Oncol; 2022 Sep; 29(9):5568-5577. PubMed ID: 35583694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.
    Merola E; Perren A; Rinke A; Zerbi A; McNamara MG; Arsenic R; Fazio N; de Herder W; Valle JW; Gress TM; Wiedenmann B; Pascher A; Pavel ME
    J Neuroendocrinol; 2022 Oct; 34(10):e13193. PubMed ID: 36306194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.
    Merola E; Falconi M; Rinke A; Staettner S; Krendl F; Partelli S; Andreasi V; Gress TM; Pascher A; Arsenic R; Doglioni C; Kaemmerer D; Wiedenmann B; Pavel ME
    Am J Surg; 2020 Aug; 220(2):284-289. PubMed ID: 32209239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
    Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
    Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of CT-based radiomics in grade 1-2 pancreatic neuroendocrine tumors.
    Heo S; Park HJ; Kim HJ; Kim JH; Park SY; Kim KW; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
    Cancer Imaging; 2024 Feb; 24(1):28. PubMed ID: 38395973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
    Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
    Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
    Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
    J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Li Y; Fan G; Yu F; Tian C; Tan H
    Neuroendocrinology; 2021; 111(12):1231-1237. PubMed ID: 33370727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.